Cardiopulmonary bypass (CPB) is a medical technique that temporarily takes over the function of the heart and lungs during cardiac surgery, allowing surgeons to perform intricate procedures on the heart. This sophisticated procedure involves diverting the patient's blood away from the heart and lungs, using a heart-lung machine that takes over the oxygenation and circulation of blood throughout the body. The machine removes carbon dioxide and adds oxygen to the blood, mimicking the natural functions of the heart and lungs. By employing CPB, surgeons can operate on a motionless and bloodless heart, facilitating complex cardiac surgeries that would be otherwise challenging or impossible. While essential for many cardiac procedures, the use of cardiopulmonary bypass does carry some risks, and ongoing research focuses on optimizing its techniques to minimize potential complications and enhance patient outcomes. The development of this technology has significantly advanced the field of cardiac surgery, enabling life-saving interventions and improving the overall success of complex heart surgeries.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India